Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Enteral Glutamine Supplementation on Mortality and Infectious Morbidity in Severely Burned Patients: a Multi-center Pilot Trial
Brief Summary: The purpose of this study is to test the following hypotheses:

1. Enteral glutamine administration decreases in-hospital mortality in adult patients with severe thermal burn injuries.
2. Enteral glutamine administration decreases hospital-acquired blood stream infections from Gram negative organisms and length of stay in ICU and hospital for adult patients with severe thermal burn injuries.
3. Enteral glutamine administration will improve the physical function of surviving burn injured patients and reduce their cost of care.

The objectives of this trial are to determine the overall treatment effect and safety of glutamine in burn patients. Specifically, the investigators want to assess the following outcomes in a sample of 1200 patients in 80 sites:

1. In patients with severe, life-threatening burn injury, what is the effect of enteral glutamine on time to discharge alive from hospital
2. In patients with severe, life-threatening burn injury, what is the effect of enteral glutamine on 6 month mortality, hospital-acquired blood stream infections from Gram negative organisms, hospital mortality, duration of stay in ICU and hospital, health-related quality of life, and health care resources?


Options:
A: Arm Label: Glutamine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Total Parenteral Nutrition with Glutamine | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Total Parenteral Nutrition without glutamine | Intervention Type: DIETARY_SUPPLEMENT; Name: Total Parenteral Nutrition with Glutamine; Assigned to Arm(s): Glutamine | Intervention Type: OTHER; Name: Total Parenteral Nutrition without glutamine; Assigned to Arm(s): Control
B: Arm Label: Enteral Glutamine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Enteral Glutamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Enteral Glutamine; Assigned to Arm(s): Enteral Glutamine | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Glutamine; Type: EXPERIMENTAL; Interventions: Other: Glutamine | Arm Label: Antioxidants; Type: EXPERIMENTAL; Interventions: Other: Antioxidants | Arm Label: Glutamine + Antioxidants; Type: EXPERIMENTAL; Interventions: Other: Glutamine + Antioxidants | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Glutamine; Assigned to Arm(s): Glutamine | Intervention Type: OTHER; Name: Antioxidants; Assigned to Arm(s): Antioxidants | Intervention Type: OTHER; Name: Glutamine + Antioxidants; Assigned to Arm(s): Glutamine + Antioxidants | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: alanyl-glutamine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dipeptiven | Arm Label: normal saline; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: normal saline | Intervention Type: DIETARY_SUPPLEMENT; Name: Dipeptiven; Assigned to Arm(s): alanyl-glutamine | Intervention Type: DIETARY_SUPPLEMENT; Name: normal saline; Assigned to Arm(s): normal saline

Answer: B